絞り込み

16406

広告

Frequency of discontinuation of injectable osteoporosis therapies in US patients over 2 years.

著者 Modi A , Sajjan S , Insinga R , Weaver J , Lewiecki EM , Harris ST
Osteoporos Int.2017 Jan 05 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (104view , 0users)

Full Text Sources

Miscellaneous

Little is known about treatment patterns with injectable osteoporosis therapies. At 12 months, the probability of discontinuation was 69.1% among patients using ibandronate, followed by teriparatide (67.1%), zoledronic acid (59.2%), and denosumab (48.8%). By 24 months, discontinuation was higher for each treatment. The majority of US patients discontinue injectable osteoporosis treatment by the end of the first year following initiation.
PMID: 28058444 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード